Editas Medicine Priced, Nasdaq: EDIT

Developing gene editing therapies based on CRISPR/Cas9 technology.

Industry: Health Care

Latest Trade: $15.82 0.00 (0.0%)

First Day Return: +13.8%

Return from IPO: -1.1%

Industry: Health Care

We are a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. We believe that we have entered a new era of genomic medicine as the growth of genomic information in recent decades has significantly expanded the understanding of genetically defined diseases. A new technology known as CRISPR (clustered, regularly interspaced short palindromic repeats)/Cas9 (CRISPR associated protein 9) has the potential to achieve precise, directed changes in DNA. The confluence of these two streams of scientific endeavor, understanding genetic defects and having the tools to be able to address them, creates the opportunity for us to achieve a longstanding goal of medicine: to treat the root causes of diseases at the genetic level. While genetic defects are now recognized as the causes of many diseases, the vast majority of these diseases lack effective treatments. Of the estimated 6,000 diseases that are known to be caused by genetic mutations, we believe fewer than 5% are served by approved therapies. Our mission is to translate the promise of our science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
more less
IPO News for Editas Medicine
more
IPO Data
IPO File Date 01/04/2016
Offer Price $16.00
Price Range $16.00 - $18.00
Offer Shares (mm) 5.9
Deal Size ($mm) $94
IPO Data
IPO Date 02/02/2016
Offer Price $16.00
Price Range $16.00 - $18.00
Offer Shares (mm) 5.9
Deal Size ($mm) $94
Underwriters
more
Company Data
Headquarters Cambridge, MA
Founded 2013
Employees 55
Website www.editasmedicine.com